Time-Dependent Protection of CB2 Receptor Agonist in Stroke.

Recent studies have indicated that type 2 cannabinoid receptor (CB2R) agonists reduce neurodegeneration after brain injury through anti-inflammatory activity. The purpose of this study was to examine the time-dependent interaction of CB2R and inflammation in stroke brain. Adult male rats were subjec...

Full description

Bibliographic Details
Main Authors: Seong-Jin Yu, David Reiner, Hui Shen, Kou-Jen Wu, Qing-Rong Liu, Yun Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4505877?pdf=render
_version_ 1818908099366354944
author Seong-Jin Yu
David Reiner
Hui Shen
Kou-Jen Wu
Qing-Rong Liu
Yun Wang
author_facet Seong-Jin Yu
David Reiner
Hui Shen
Kou-Jen Wu
Qing-Rong Liu
Yun Wang
author_sort Seong-Jin Yu
collection DOAJ
description Recent studies have indicated that type 2 cannabinoid receptor (CB2R) agonists reduce neurodegeneration after brain injury through anti-inflammatory activity. The purpose of this study was to examine the time-dependent interaction of CB2R and inflammation in stroke brain. Adult male rats were subjected to right middle cerebral artery occlusion (MCAo). CB2R mRNA expression was significantly elevated >20 fold on day 2, peaked >40-fold on day 5, and normalized on day 10 post-stroke. Inflammatory markers IBA1 and TLR4 were significantly upregulated 15 fold until day 5 after MCAo. Because of the delayed upregulation of CB2R and IBA1, we next treated animals daily with CB2R agonist AM1241 or anti-inflammatory PPAR-γ agonist pioglitazone from 2 to 5 days after MCAo. Delayed treatment with pioglitazone significantly reduced abnormal neurological scores and body asymmetry as well as brain infarction in stroke animals. No behavioral improvement or reduction in brain infarction was found in animals receiving AM1241. Pioglitazone, but not AM1241, significantly reduced IBA1 expression in the stroke cortex, suggesting that delayed treatment with AM1241 failed to alter ischemia-mediated IBA-1 upregulation. In contrast, pretreatment with AM1241 significantly reduced brain infarction and neurological deficits. In conclusion, our data support a time-dependent neuroprotection of CB2 agonist in an animal model of stroke. Delayed post- treatment with PPAR-γ agonist induced behavioral recovery and microglial suppression; early treatment with CB2R agonist suppressed neurodegeneration in stroke animals.
first_indexed 2024-12-19T22:05:38Z
format Article
id doaj.art-43fd890797fb461bb7c6b5125498b35c
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-19T22:05:38Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-43fd890797fb461bb7c6b5125498b35c2022-12-21T20:04:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013248710.1371/journal.pone.0132487Time-Dependent Protection of CB2 Receptor Agonist in Stroke.Seong-Jin YuDavid ReinerHui ShenKou-Jen WuQing-Rong LiuYun WangRecent studies have indicated that type 2 cannabinoid receptor (CB2R) agonists reduce neurodegeneration after brain injury through anti-inflammatory activity. The purpose of this study was to examine the time-dependent interaction of CB2R and inflammation in stroke brain. Adult male rats were subjected to right middle cerebral artery occlusion (MCAo). CB2R mRNA expression was significantly elevated >20 fold on day 2, peaked >40-fold on day 5, and normalized on day 10 post-stroke. Inflammatory markers IBA1 and TLR4 were significantly upregulated 15 fold until day 5 after MCAo. Because of the delayed upregulation of CB2R and IBA1, we next treated animals daily with CB2R agonist AM1241 or anti-inflammatory PPAR-γ agonist pioglitazone from 2 to 5 days after MCAo. Delayed treatment with pioglitazone significantly reduced abnormal neurological scores and body asymmetry as well as brain infarction in stroke animals. No behavioral improvement or reduction in brain infarction was found in animals receiving AM1241. Pioglitazone, but not AM1241, significantly reduced IBA1 expression in the stroke cortex, suggesting that delayed treatment with AM1241 failed to alter ischemia-mediated IBA-1 upregulation. In contrast, pretreatment with AM1241 significantly reduced brain infarction and neurological deficits. In conclusion, our data support a time-dependent neuroprotection of CB2 agonist in an animal model of stroke. Delayed post- treatment with PPAR-γ agonist induced behavioral recovery and microglial suppression; early treatment with CB2R agonist suppressed neurodegeneration in stroke animals.http://europepmc.org/articles/PMC4505877?pdf=render
spellingShingle Seong-Jin Yu
David Reiner
Hui Shen
Kou-Jen Wu
Qing-Rong Liu
Yun Wang
Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
PLoS ONE
title Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
title_full Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
title_fullStr Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
title_full_unstemmed Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
title_short Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
title_sort time dependent protection of cb2 receptor agonist in stroke
url http://europepmc.org/articles/PMC4505877?pdf=render
work_keys_str_mv AT seongjinyu timedependentprotectionofcb2receptoragonistinstroke
AT davidreiner timedependentprotectionofcb2receptoragonistinstroke
AT huishen timedependentprotectionofcb2receptoragonistinstroke
AT koujenwu timedependentprotectionofcb2receptoragonistinstroke
AT qingrongliu timedependentprotectionofcb2receptoragonistinstroke
AT yunwang timedependentprotectionofcb2receptoragonistinstroke